Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 3/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22977761 | 0.75 | CDA (0.39) | GAAHPGDL3MBTL1ALDH1A1CYP2C19 | |
| SCHEMBL632889 | 0.75 | MPO (0.37) | — | |
| SCHEMBL30796037 | 0.75 | KDM5A (0.33) | HPGDSMN1; SMN2STAT3HTTC5AR1 | |
| SCHEMBL634137 | 0.67 | ALDH1A1 (0.37) | GAAHPGDL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL634040 | 0.67 | ALDH1A1 (0.34) | GAAHPGDL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL633036 | 0.67 | GAA (0.37) | GAAHPGDL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL632613 | 0.67 | ALDH1A1 (0.43) | GAAL3MBTL1ALDH1A1CYP2C19C5AR1 | |
| SCHEMBL15167135 | 0.66 | TRPV3 (0.40) | SMN1; SMN2STAT3HTT | |
| SCHEMBL633188 | 0.66 | HMOX1 (0.36) | — | |
| SCHEMBL633430 | 0.66 | GAA (0.43) | GAAHPGDL3MBTL1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419418-B1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2419418-B1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-15 | — | — | EP | disclosed |
| US-8324186-B2 | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8324186-B2 | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8324186-B2 | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-04 | — | — | US | disclosed |
| EP-2419418-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010121036-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010121036-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR2 | GAA 3373/4885HPGD 782/4885L3MBTL1 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.